HIV, Merck

Merck's HIV treatment meets main goal in two late-stage studies
Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in adults receiving another form of therapy in two late-stage studies, the company said on Thursday.
Merck posts mixed late-stage trial results for HIV treatment
Merck (NYSE:MRK) on Thursday indicated a mixed outcome in two pivotal Phase 3 trials for its experimental HIV therapy islatravir, administered orally in combination with its FDA-approved HIV therapy doravirine as a once-daily single-tablet regimen.
Merck's HIV combo treatment meets the bar for viral suppression in pair of phase 3 studies
However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's top-selling Biktarvy in one of the studies.
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials
Merck & Co Inc (NYSE:MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection. The trials included patients who were virologically suppressed on different antiretroviral therapy regimens,
MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals
Merck decided to evaluate a lower dose of its HIV candidate islatravir in a phase III program several months after the FDA put studies on the candidate on hold last year. While six studies on ...
The Pharma Letter2d
Merck & Co buoyed by Phase III results with HIV tablet
US pharma giant Merck has announced top-line results from two pivotal Phase III trials of the investigational, once-daily, ...
Merck’s doravirine/islatravir combination meets efficacy endpoint in HIV-1
Merck (MRK) announced topline results from two pivotal Phase 3 trials of the investigational, oral, two-drug, single-tablet regimen of ...
Monthly Prescribing Reference3d
Doravirine/Islatravir Noninferior to Baseline ART in Adults With Virologically-Suppressed HIV-1
The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor.
Merck's HIV treatment meets main goal of two late-stage studies
U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...
Merck Reports Topline Data From Phase 3 Trials Of Doravirine + Islatravir To Treat HIV-1 Infection
(RTTNews) - Merck & Co Inc. (MRK), Thursday reported topline results from two pivotal Phase 3 trials evaluating the company's drug candidate islatravir in combination with its approved HIV drug ...